The Bronchiolitis Obliterans drugs in development market research report provides comprehensive information on the therapeutics under development for Bronchiolitis Obliterans, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Bronchiolitis Obliterans. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Bronchiolitis Obliterans and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Bronchiolitis Obliterans by ten companies/universities/institutes. The top development phase for Bronchiolitis Obliterans is phase iii with four drugs in that stage. The Bronchiolitis Obliterans pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Bronchiolitis Obliterans pipeline products market are: Boehringer Ingelheim International, F. Hoffmann-La Roche and Novartis.
The key targets in the Bronchiolitis Obliterans pipeline products market include Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2), Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2), and Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 2.7.10.2).
The key mechanisms of action in the Bronchiolitis Obliterans pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with one drug in Phase III. The Bronchiolitis Obliterans pipeline products include three routes of administration with the top ROA being Inhalational and two key molecule types in the Bronchiolitis Obliterans pipeline products market including Small Molecule, and Recombinant Protein.
Bronchiolitis Obliterans overview
Bronchiolitis Obliterans also known as popcorn lung is a rare chronic disease causing the obstruction of small airways thereby declining the activity of lungs. It is one of the complications after lung transplant and hematopoietic stem cell transplantation. Inhalation of toxic chemicals like acetaldehyde, formaldehyde, ammonia, chlorine, nitrogen oxides etc. and associated with autoimmune disorders. When exposed to toxins or certain infections bronchioles becomes injured causing the build-up of scar tissue and leading to disability in absorbing oxygen. The most common symptoms associated are SOB, dry cough, fatigue, wheezing, skin rash etc. Diagnosed based on the symptoms and imaging studies, CT scan, chest X-ray, lung biopsy if needed. If caused because of transplantation complication immunosuppressants are prescribed, corticosteroids in combination and other symptomatic treatment provided.
For a complete picture of Bronchiolitis Obliterans’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
